At a glance
ClinicalIndex Comparison RecordN/ACompleted· 312 enrolled
Drug / intervention
XIENCE PRIME SV Everolimus Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance
In Brief
An observational study evaluating XIENCE PRIME SV Everolimus Eluting Coronary Stent for Ischemic Heart Disease and 4 related conditions. Completed, enrolled 312 participants across 33 sites.
Detailed Summary
The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion, Myocardial Ischemia
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedAug 2015
Primary CompletionSep 2019
TodayJul 2026
First PostedAug 3, 2015
Enrollment StartMay 13, 2013
Primary CompletionSep 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.9 years ago
Interventions
XIENCE PRIME SV Everolimus Eluting Coronary Stentdevice
Patients receiving XIENCE PRIME SV Everolimus Eluting Stent